Category one submissions will be for medicines considered to have significant "added therapeutic value" - this categorisation system negotiated with the industry explicitly and objectively prioritises the needs of some patients over others. …
Latest Video
New Stories
-
PhRMA: The risk of international reference pricing
July 18, 2019 - - Latest News -
J&J Innovation recognises undergraduates
July 18, 2019 - - Latest News -
Stakeholder meeting a little different to last time
July 18, 2019 - - Latest News -
Takeda: From CAR-T to off-the-shelf iCAR-T
July 18, 2019 - - Latest News -
GBMA confirms its first 'biosimilar' member
July 18, 2019 - - Latest News -
Bayer venture capital arm invests in 'off the shelf' CAR-T
July 17, 2019 - - Latest News -
Servier in new collaboration with Melbourne's BioCurate
July 17, 2019 - - Latest News